一上市公司全体高管自愿降薪，董事长降50%

Core Viewpoint - The company, Shuoshi Biotechnology, announced voluntary salary reductions for its board members and senior management, reflecting their commitment to navigate industry challenges and enhance long-term development [2] Group 1: Salary Adjustments - The salary reductions range from 5% to 50%, effective from August 15, 2025, with the chairman and general manager's salary reduced by 50% [2] - Specific reductions include a 40% cut for two vice presidents, a 10% cut for the financial director, and a 5% cut for one employee supervisor [2] Group 2: Financial Performance - In 2024, the company reported a revenue of 350 million yuan, a year-on-year decline of 13.29%, and a net profit loss of 2 million yuan, although this represented a significant reduction in losses compared to the previous year [3] - The company experienced a sharp decline in net profit in 2023, with a loss of 374 million yuan, a 120.45% decrease year-on-year [3][5] Group 3: R&D and Market Strategy - The company increased its R&D investment to 28.86% of revenue in 2024, focusing on product line optimization and new solutions in infectious disease prevention and cancer diagnostics [6] - Despite a 37.89% increase in overseas revenue, the overall contribution of international sales remains limited, failing to offset the decline in the domestic market [6]